GILDGilead SciencesRunning, no new patients
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Metastatic Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 227 (final count)
- Started
- Oct 15, 2019
- Main results expected
- Jan 15, 2025
- Fully finished
- Dec 2026
- Results posted
- Jan 30, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment
Measured over: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03964727 · record last updated 2026-04-28 · checked 2026-11-09 15:47 UTC